contact us
subTop OurProjects

Ureteric strictures result from fibrosis in the wall of the ureter, resulting in narrowing of the utereric lumen which could in turn lead to significant morbidity and loss of a functioning kidney. Treatment (and prevention) involves placing a ureteric stent within the ureter for up to 6 weeks, which is then removed.

Current stents serve only as passive internal scaffolds and do not address any pathology e.g. fibrosis, infection, tumours. The team has developed a novel swellable hydrogel coating which can be applied to commercially available stents, which allows drug elution of mitomycin C (MMC) to prevent fibrosis.

Project Deliverables

A MMC-loaded stent coating which has been tested for the following: i) safety and feasibility of insertion/removal of the stent in a pig model, ii) quantification of the drug concentration of MMC delivered by the coated stent in ureteric tissue, and iii) efficacy of MMC in preventing stricture formation.

Principal Investigator: Dr CHONG Tsung Wen

Institution: Singapore General Hospital

NHIC Ref: NHIC-I2D-1506051



See all BIOPHARMA projects >